Business context and reporting period
Filing identity mismatch: The supplied filing is Signal Genetics, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, filed March 27, 2015. It does not identify Viridian Therapeutics, Inc.; confirm the issuer before relying on this summary.
Signal Genetics was a commercial-stage molecular diagnostics company focused on multiple myeloma (MM). Its principal service was MyPRS, a gene-expression test intended to support prognosis and treatment decisions. The company reported one business segment and U.S. operations.
Financial results and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Net revenue | $4.320 million | $4.316 million |
| Cost of revenue | $3.243 million | $2.778 million |
| Gross profit / margin | $1.077 million / 25% | $1.538 million / 36% |
| Operating expenses | $11.187 million | $4.513 million |
| Operating loss | $6.867 million | $0.197 million |
| Interest expense | $1.023 million | $1.963 million |
| Net loss attributable to stockholders/members | $7.890 million | $2.445 million |
| Net loss per share | $3.50 | $12.23 |
| Cash used in operating activities | $2.213 million | $1.168 million |
- Cash at year-end was $5.119 million, versus $0.209 million a year earlier; working capital was $4.8 million. Total assets were $8.089 million and total liabilities $2.098 million.
- Year-end current liabilities included $1.045 million due to a related party, payable on demand, and $80,000 of current capital-lease obligations. The company had no material capital-expenditure commitments.
- The filing reports $4.298 million of noncash stock compensation in 2014, including $3.904 million in general and administrative expense. The $27.326 million related-party debt conversion into equity substantially reduced reported liabilities.
Material changes versus the prior comparable period
- Revenue was essentially flat, while tests billed increased 9.9% to 4,196. Cost of revenue rose 17%, reducing gross margin to 25% from 36%.
- General and administrative expense increased to $7.034 million from $1.411 million, driven principally by stock compensation, staffing, public-company costs, headquarters and IT expenses, and bad debt. Selling and marketing expense more than doubled to $717,000 as the company expanded its sales team.
- Net loss attributable to stockholders/members increased to $7.890 million from $2.445 million. Operating cash use increased to $2.213 million from $1.168 million.
- Revenue adjustments included $380,000 of unfavorable changes to prior-period non-contracted revenue estimates in 2014, versus $57,000 in 2013. The filing also describes a $177,000 bad-debt expense related to uncollectible receivables.
- In June 2014, the company completed its corporate conversion and IPO, receiving approximately $6.1 million net proceeds. It converted $27.3 million of related-party debt into equity. MyPRS received New York approval, and the UAMS laboratory services agreements were extended through September 2017.
Outlook, commentary, risks and unusual items
- Management forecast continued losses and negative operating cash flows, estimating that cash on hand would fund operations for at least 12–15 months from the report date. It expected to seek further financing or strategic investment and cautioned that funding might not be available on acceptable terms.
- After year-end, the company completed a February 2015 follow-on offering, including the underwriters’ overallotment, for approximately $9.3 million net proceeds. On March 6, 2015, the related-party balance was converted into a $1.1 million unsecured, 8% demand note, not callable before June 30, 2015.
- MyPRS sales were highly concentrated: UAMS-sourced revenue represented 84% of 2014 net revenue, and UAMS-related receivables were 63% of year-end receivables. The company also cited reliance on a single supplier for inventory used in testing and on its sole laboratory facility.
- Key risks include uncertain payer coverage and reimbursement, collection delays and estimation uncertainty, possible FDA oversight of laboratory-developed tests, dependence on adoption by physicians, competition, and the need for additional capital. Management planned to expand payer contracts, sales coverage and testing offerings, but provided no quantified revenue, earnings or cash-flow guidance.
- Other notable items: a $100,000 gain on legal settlement in 2014; a $50,000 letter of credit secured by restricted cash; and a 2014 restatement of quarterly weighted-average shares and loss per share. The filing says prior interim statements were not materially misstated and were not amended. Management stated that a material weakness in financial-reporting controls identified in 2013 had been remediated by year-end 2014; the auditor did not attest to internal-control effectiveness.
Most important facts for investors to verify
- Confirm the issuer: this document is Signal Genetics, Inc., not Viridian Therapeutics, Inc.
- Review the full audited statements and notes, especially the stock-compensation charges, prior-period revenue adjustments, receivable aging and restated quarterly loss-per-share data.
- Assess cash runway and financing needs using the year-end cash balance together with the subsequent $9.3 million offering and related-party note terms.
- Evaluate reliance on UAMS, the sustainability of reimbursement and collections, and the economics of MyPRS given the declining gross margin.
- Check subsequent filings for actual progress on payer coverage, sales growth, new tests, regulatory requirements and the claimed remediation of internal controls.